Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2497282 | 0.97 | — | — | |
| Bromide SCHEMBL2350294 | 0.95 | CARM1 (0.32) | HRH3KMT2AKDM4EALDH1A1CARM1 | |
| SCHEMBL48583 | 0.92 | — | — | |
| SCHEMBL4906908 | 0.86 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL346747 | 0.83 | HRH3 (0.43) | HRH3GAAMEN1KMT2AKDM4E | |
| SCHEMBL3314123 | 0.80 | TSHR (0.38) | HRH3GAATSHRALDH1A1CHRM5 | |
| SCHEMBL347464 | 0.80 | LMNA (0.40) | HRH3GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL762817 | 0.79 | KDM4E (0.36) | GAAKMT2ATSHRKDM4EALDH1A1 | |
| SCHEMBL346522 | 0.78 | HRH3 (0.39) | HRH3GAAMEN1KMT2AKDM4E | |
| SCHEMBL2494508 | 0.77 | TSHR (0.35) | HRH3TSHRKDM4EALDH1A1CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109478472-B | Electrolyte for electrochemical device, electrolytic solution, and electrochemical device | 大塚化学株式会社 | 2022-02-22 | — | — | CN | disclosed |
| EP-2958181-B1 | NON-AQUEOUS ELECTROLYTIC SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEM CORP (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-9653754-B2 | Nonaqueous electrolytes and nonaqueous-electrolyte secondary batteries employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2017-05-16 | — | — | US | disclosed |
| US-9620814-B2 | — | — | 2017-04-11 | — | — | US | disclosed |
| US-9515348-B2 | Nonaqueous electrolytic solution and nonaqueous-electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-12-06 | — | — | US | disclosed |
| US-9231277-B2 | Nonaqueous electrolytes and nonaqueous-electrolyte secondary batteries employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-01-05 | — | — | US | disclosed |
| EP-2958181-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2015-12-23 | — | — | EP | disclosed |
| EP-2535976-B1 | NON-AQUEOUS ELECTROLYTE SOLUTION, AND SECONDARY BATTERY COMPRISING THE SAME | MITSUBISHI CHEM CORP (JP) | 2015-09-02 | — | — | EP | disclosed |
| US-9048508-B2 | Nonaqueous electrolytes and nonaqueous-electrolyte secondary batteries employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-06-02 | — | — | US | disclosed |
| US-8933062-B2 | Nitric oxide releasing steroids | NICOX S.A. (FR) | 2015-01-13 | — | — | US | disclosed |
| WO-2003006423-A1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
| US-20020147222-A1 | Dihydropyridine derivatives | AJINOMOTO CO. INC (JP) | 2002-10-10 | — | — | US | disclosed |
| CN-1057306-C | New polypeptide compound and a process for preparation thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-10-11 | — | — | CN | disclosed |
| EP-0644199-B1 | Cyclic antimicrobial peptides and preparation thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-07-19 | — | — | EP | disclosed |
| US-5693750-A | MICROBIOCIDAL ACTION AGAINST PNEUMOCYSTIS INFECTIONS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-12-02 | — | — | US | disclosed |
| US-5569646-A | TREATMENT OF PNEUMONIA; MICROBIOCIDES, FUNGICIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-29 | — | — | US | disclosed |
| EP-0644199-A1 | Cyclic antimicrobial peptides and preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-22 | — | — | EP | disclosed |
| CN-1100104-A | New polypeptide compound and a process for preparation thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-03-15 | — | — | CN | disclosed |
| US-4975433-A | DRUG DELIVERY FOR TREATING SKIN DISORDERS | UNIVERSITY OF FLORIDA (US) | 1990-12-04 | — | — | US | disclosed |
| US-4845081-A | PRODRUGS, URACILS | UNIVERSITY OF FLORIDA (US) | 1989-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147222-A1 | Dihydropyridine derivatives | CACNA1B, CACNA1D, CACNA1C | HRH3 1086/4885GAA 1513/4885MEN1 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.